AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06165055 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DNA Sample Collection + DNA genotyping
Description: Volunteers' oral epithelial cell DNA will be collected using DNA swabs, followed by DNA isolation with the PureLink DNA Isolation Kit. The isolated DNA's quality will be assessed using the Invitrogen QUBIT 4 Fluorometer, and the samples will be stored at -20°C until analysis of specific genetic regions.
Study NCT06023186 — intervention group
Intervention type: DRUG
Intervention: mavacamten
Description: Study participants will receive mavacamten under the standard of care
Study NCT05848583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compleat 1.5
Description: EN Formula
Study NCT06448364 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07329640
Description: an anti-lymphotoxin beta receptor agonist
Study NCT06448364 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sasanlimab
Description: A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/L2
Study NCT06448364 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: a monoclonal antibody that blocks VEGF
Study NCT05677880 — intervention group
Intervention type: OTHER
Intervention: Study Procedures
Description: Participants will experience~* Neurocognitive Tests and Self-Report Measures~* Clinical Interviews~* Neurological Exam~* MRI screening at baseline, 18 months, 36 months~* Fasted Blood draw
Study NCT05114928 — intervention group
Intervention type: PROCEDURE
Intervention: Transepithelial Corneal Collagen Cross-linking
Description: Bilateral Transepithelial Corneal Collagen Cross-linking was done for all subjects using power of 9mW/cm2 at 55mm from the cornea for 10 minutes, with a total energy of 5.4j/cm2 using the (CCL VARIO, PESCHKE Trade GmbH, Huenenberg Switzerland), in the period between January 2016 to August 2016.
Study NCT05227183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The virtual version of the Social stress task : V-TSST
Description: The task consists in a brief presentation about the abilities of participants followed by an arithmetic task in front of a virtual 3D audience projected and one researcher in a room.First, participants have 5 minutes to prepare an exhibition about their qualities, their strengths and defects, and, why they identify with them. During this period virtual reality shows a closed curtain, and sounds from the audience can be heard. In the second phase, the curtain is raised and the participant must expose his speech during 5 minutes. Audience will remain attentive during 2 minutes, then audience will change to a restless attitude. The third phase consists of subtracting back a two-digit number from a four-digit number, as quickly as possible, starting again if participant makes a mistake. A debriefing of the test is scheduled at the end of the protocol, to remind patients of the purely fictional nature of this test. The visit will only end after a return to the baseline emotional state
Study NCT05197673 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Theory of planned behaviours (TPB) based intervention
Description: Intervention group will receive TPB-based education program to improve workers' attitude toward SARS-CoV-2 and raise their intention to vaccination and virus testing. The intervention will be implemented at the baseline with measurements repeated at the 3rd month, 6th month and 9th month. The standardized mode of intervention includes face-to-face/online seminar (depends on the COVID-19 situation), message via mobile phone, promotion pamphlet, etc.
Study NCT06272162 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MR guided radiotherapy
Description: 5 fractions of 10 Gray MRgRT in addition to standard of care
Study NCT04528264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative ultrasound guided
Description: Samsung Mysono U6 machine with LN 15 linear (https://www.samsunghealthcare.com/en/products/UltrasoundSystem/MySono%20U6/General%20Imaging/transducers) probe capable of Musculoskeletal imaging will be used for visualization and location of fracture after which elevation and reduction of fracture will be attempted. The ultrasound probe will be used as described by McCann. Radiographic continuity of periosteal shadow without any step will be taken as end point for reduction and the procedure will be terminated.
Study NCT04528264 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional blind reduction technique
Description: Conventional blind reduction technique
Study NCT05822908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VO659
Description: VO659 is an antisense oligonucleotide targeting CAG repeats in mRNA transcripts
Study NCT05114928 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Scheimpflug camera
Description: Pentacam (OCULUS Optikgeräte GmbH, Wetzlar, Germany) was done for all subjects at baseline and annually after TE-CXL till 5 years of follow-up.
Study NCT04573712 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow up and Assessment
Description: each patient should wear an actigraph during a week and will be do some tests during 2hours (6min walk, apathy inventory, fatigue severity scale etc...)
Study NCT06399055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-387
Description: 1 Tablet
Study NCT06399055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D484
Description: 1 Tablet
Study NCT06041321 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reparel Sleeve
Description: For the purpose of this study, the Reparel Sleeve will be evaluated against a placebo sleeve of similar feel, texture, and look. The indication is that due to its technology, the Reparel sleeve will allow for the ability to reflect energy using a blend of semi-conductors grounded to nanoparticles interwoven between fibers of the sleeve. Thermal energy is then absorbed from the patient thus activating electrons on the nanoparticles and releasing photonic energy directed at tissues within the surrounding area7. This photostimulation is expected to alleviate pain and inflammation while promoting wound healing as well as tissue regeneration.
Study NCT06041321 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Sleeve
Description: Generic sleeve used as a placebo. This placebo will have a similar feel, texture, and look with no additional technology.
Study NCT05962021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab plus Chemotherapy
Description: Therapy was administered on a 21-day regimen for 3 cycles, with Toripalimab (240mg, d1), carboplatin (AUC=5, d1) + pemetrexed (500 mg/m2, d1) for patients with lung adenocarcinoma and carboplatin (AUC=5, d1) + albumin-bound paclitaxel (260 mg/m2, d1) for patients with other subtypes.
Study NCT05607017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Taken Orally
Study NCT05607017 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Photon Radiation Therapy
Study NCT06224881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ascorbic acid
Description: 2 gm every 8hrs for 4 days
Study NCT06224881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic acid
Description: 2 gm every 8hrs for 4 days
Study NCT03567694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA115
Description: Test Drug
Study NCT03567694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT04956757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Scapula retraction exercises at varying shoulder abduction angles will be applied
Study NCT04679454 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Phase I
Description: To establish the recommended dose defined as the maximum tolerated dose (MTD)The dose-limiting toxicity (DLT) is defined as any G3-G4 event according to NCI CTCAE Version 4.03 scale. Dose escalation is designed as a 3+3 rule-based study. Dose escalation will be initiated from a baseline dose of 18 Gy and increased to reach 21 Gy and 24 Gy. The population size includes 18 patients.
Study NCT04679454 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Phase II
Description: The recommended dose from the phase I study is delivered, using Cyberknife in order to evaluate the efficacy measured in terms of pCR rate. The population size includes 61 patients.
Study NCT04863430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 500mg oral qd
Study NCT04863430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m\^2 administered as IV infusion on Days 1 of each 21-day cycle
Study NCT04863430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: According to body surface area,(\<1.5m\^2) 40mg or (≥1.5m\^2)50mg bid oral on Day 1-14 of each 21-day cycle
Study NCT05152472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg
Description: (Intravenous administration)
Study NCT05152472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib 400 MG
Description: (Per os)
Study NCT05152472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib 400 MG
Description: (Per os)
Study NCT05890287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide+ exemestane/Fulvestrant/Letrozole/Anastrozole/Tamoxifen
Study NCT04423614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Inspiratory muscle training exercises, performed 5 times a week for 2-4 weeks prior to cardiac surgery.
Study NCT04423614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation Breathing
Description: Relaxation breathing exercises, performed 5 times a week for 2-4 weeks prior to cardiac surgery.
Study NCT05671601 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Automatic picture recognition
Description: A machine that processes photographs automatically taken
Study NCT05671601 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Manual Assessment Group
Description: Manual recognition of pictures
Study NCT05059418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonazepam 0.5 MG
Description: Topical treatment of oral mucosa with lozenge pill
Study NCT05059418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin Topical
Description: Topical treatment of oral mucosa with capsaicin rinse
Study NCT05059418 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mouth rinse with no capsaicin
Study NCT00608816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinephrine
Description: Epinephrine 0.06 µg/kg/min infusion during a two hour experimental period on Day 2
Study NCT00608816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinephrine
Description: Epinephrine 0.06 µg/kg/min infusion during two hour experimental period on Day 2
Study NCT04773665 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VBI-2902a
Description: VBI-2902a is an intramuscular injection of VBI-2902a investigational enveloped virus-like particle COVID-19 vaccine with aluminum phosphate adjuvant.
Study NCT04773665 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride
Study NCT04773665 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride
Study NCT04773665 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VBI-2905a
Description: VBI-2905a is an intramuscular injection of VBI-2905a investigational enveloped virus-like particle COVID-19 vaccine with aluminum phosphate adjuvant.
Study NCT06389175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous non-invasive vagus nerve stimulation (tVNS)
Description: Participants receive tVNS during the neuroimaging sessions and the extended stimulation period. To stimulate vagal afferents, the electrode will be placed at the cymba conchae of the right ear using a previously established, conventional stimulation protocol (25 Hz, 30s on/30s off cycle; NEMOS device, Cerbomed, Erlangen, Germany). To improve blinding, the stimulations intensities will be adjusted to correspond to a mild pricking sensation for tVNS and sham.~The extended stimulation period in the experimental group involves six sessions with at least 1.5h of stimulation (stimulation in the lab or at home with home device using the same stimulation protocol as during the neuroimaging sessions; tVNS R device, tVNS Technologies GmbH, Erlangen, Germany).
Study NCT06389175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham stimulation
Description: The control intervention consists of a sham stimulation. In the neuroimaging session the electrode will be placed upside down to stimulate the earlobe, which is not innervated by vagal afferent fibers. To improve blinding, the same stimulation protocol as for the tVNS will be applied (25 Hz, 30s on/30s off cycle; NEMOS device, Cerbomed, Erlangen, Germany) and stimulation intensities will be adjusted to correspond to a mild pricking sensation.~During the extended stimulation period, the electrode will be placed at the cymba conchae, but only receive a low-intensity stimulation below the perception threshold (0.1mA). To ensure blinding, participants will be instructed that the extended stimulation period will examine the effects of a low- vs. high-intensity tVNS protocol. Each repeated stimulation period will involve six sessions with at least 1.5h of low-intensity stimulation (stimulation in the lab or at home with home device; tVNS R device, tVNS Technologies GmbH, Erlangen, Germany).
Study NCT05460182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAF+CTG
Description: Coronally Advanced Flap + Connective Tissue Graft
Study NCT04913779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-SARS-CoV-2
Description: Purified F(ab')2 Fragments of Equine hyperimmune Serum with anti-SARS-CoV-2 neutralizing activity (titer 1/5120 or higher)
Study NCT04913779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of 10 ml of a control-solution without neutralizing activity against SARS-CoV-2, administered in slow intravenous infusion (10 ml diluted in 100 ml of saline solution, administered over 50 to 60 minutes in slow drip), produced by ANLIS-Malbrán, administered twice (time 0 when incorporated into the study -initial dose- and at 48 hours -second dose-).
Study NCT05460182 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAF
Description: Coronally Advanced Flap
Study NCT04675827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab and tratuzumab fixed dose combination
Description: Treatment administration: adjuvant pertuzumab and trastuzumab fixed dose combination SC for 14 cycles
Study NCT04675827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: Treatment administration: adjuvant T-DM1 for 14 cycles.
Study NCT06476678 — intervention group
Intervention type: DEVICE
Intervention: Speedboat™ Ultraslim
Description: Use of Speedboat™ Ultraslim for performing endoscopic submucosal dissection of esophageal lesions.
Study NCT05559099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tecovirimat Oral Capsule
Description: 200 mg capsules~Number of capsules and frequency of dosage will be based on participant weight:~* ≥120 kg: three capsules three times a day (total daily tecovirimat dose: 1,800 mg)~* 40 to \<120 kg: three capsules twice a day (total daily tecovirimat dose: 1,200 mg)~* 25 to \<40 kg: two capsules twice a day (total daily tecovirimat dose: 800 mg)~* 13 to \<25 kg: one capsule twice a day (total daily tecovirimat dose: 400 mg)~* 6 to \<13 kg: ½ the contents of a capsule twice daily (total daily tecovirimat dose: 200 mg)~* 3 to \<6 kg: ¼ the contents of a capsule twice daily (total daily tecovirimat dose: 100 mg)
Study NCT05559099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules to match tecovirimat
Study NCT03827941 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1 Hz Auricular transcutaneous electrical nerve stimulation
Description: High-functioning individuals with autism randomized to this group will receive 1 Hz tVNS stimulation for 30 minutes/day up to 5 times/week for 3 weeks.
Study NCT03827941 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 20 Hz Auricular transcutaneous electrical nerve stimulation
Description: High-functioning individuals with autism randomized to this group will receive 1 Hz tVNS stimulation for 30 minutes/day up to 5 times/week for 3 weeks.
Study NCT05497141 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System
Description: Subjects who received Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System will be included in this arm. The Neoblazar® is intended for reconstruction of the insufficient tricuspid valve through tissue tissue approximation.
Study NCT05364905 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy
Description: Patients with confirmed advanced, recurrent or metastatic endometrial cancer, treated by chemotherapy in real life-setting, between 1st January 2019 to 31rd December March 2019, in first or second line of chemotherapy.
Study NCT06225388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression socks
Description: A pair of socks corresponding to the intervention allocated will be given to the participant, by an investigator who will not participate in the evaluation, in a dark plastic bag to avoid any visual influence. We will adopt strategies to prevent information about the socks from influencing the participants' behaviour: (1) the compression and placebo socks will have the same colour, any visual detail and branding will be covered. Words or logos from the compression sock will be covered, so participants are unable to differentiate them. (2) After performing the running protocol, participants will remove their socks and return them to the investigator.
Study NCT06225388 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo socks
Description: The compression and placebo socks will have the same colour, any visual detail and branding will be covered. Words or logos from the compression sock will be covered, so participants are unable to differentiate them. (2) After performing the running protocol, participants will remove their socks and return them to the investigator.
Study NCT05625334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA
Description: powder for oral inhalation via a Dry Powder Inhaler (DPI)
Study NCT05625334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non-enteric-coated chewable aspirin
Description: Orally administered
Study NCT05448807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OraVerse
Description: Phentolamine mesylate is a vaso-dilator that was used for treating dermal necrosis and severe hypertension cases since 1952. It is alpha-adrenergic antagonist. Oraverse is supplied in a dose equal to the amount of LA taken in adults and children with weights more than 30 kg. While in children less than 30 kg, it is advised to use only half carpule according the manufacturer's instructions.
Study NCT04834973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tigilanol tiglate
Description: Single or multiple Intratumoural treatment of tigilanol tiglate at escalating doses of 0.6 mg/m2, 1.2 mg/m2 and 2.4 mg/m2.~Tigilanol tiglate is a novel, short-chain diterpene ester in early clinical development for local treatment of a wide range of solid tumours.
Study NCT04834973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Three weekly 200 mg intravenous pembrolizumab treatment.~Pembrolizumab is a systemic anti-programmed cell death receptor 1 (PD 1) immunotherapy.
Study NCT04830800 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVIVAC
Description: COVIVAC vaccine, manufactured by IVAC with or without adjuvant CpG1018 for prevention of COVID-19
Study NCT04830800 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate-buffered saline
Description: Phosphate buffer solution (pH 7.2), manufactured by IVAC
Study NCT05881772 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation
Description: It will be applied a dose of laser radiation through a cluster with four diodes, wavelength of 830 nm and power of 800mW (200mW/diode), HTM® (model Fluence MAXX, São Paulo, Brazil). For application, the patient will be positioned in a sitting position and the treatment will be performed with the fixed probe in contact with the skin at an angle of 90º, using the continuous emission mode. The therapy will be applied to the quadriceps muscle, bilaterally.
Study NCT05881772 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Photobiomodulation
Description: It will be applied a dose of laser radiation through a cluster with four diodes, wavelength of 830 nm and power of 800mW (200mW/diode), HTM® (model Fluence MAXX, São Paulo, Brazil). For application, the patient will be positioned in a sitting position and the treatment will be performed with the fixed probe in contact with the skin at an angle of 90º, using the continuous emission mode. The therapy will be applied to the quadriceps muscle, bilaterally.
Study NCT04765137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin Oral Tablet
Description: Atorvastatin pill 40 mg to be taken every night